Spinal muscular atrophy (SMA) is the leading genetic cause of death for infants.1,2 Digital necrosis is an ultra-rare manifestation of this disease, and its etiology has yet to be elucidated.4,5 We present a child who was referred to genetics for extensive digital necrosis after cardiac surgery. The infant was ultimately diagnosed with SMA by single gene testing that revealed a homozygous deletion of exons 7 and 8 on the SMN1 gene. SMA is a motor neuron disorder typically presenting with neurologic symptoms but should be considered in any infant with digital necrosis.
Case report
The child was born uneventfully to a family with an unremarkable medical history. At age 1 month, he presented with failure to thrive. Workup revealed a large atrial septal defect and multiple ventricular septal defects. Pulmonary artery banding was performed at age 2 months. Postoperatively, he required intubation for 3 weeks. He also developed severe necrosis of all 10 toes (figure, A). A hypercoagulation panel was normal. A Doppler ultrasound revealed a left femoral clot, which was successfully treated with anticoagulation, aspirin, and nitroglycerin. However, the necroses progressed, and no cause was initially identified. Allowing autoamputation of the toes was recommended. He was discharged home at age 4 months on gastrostomy tube feeds. By then, developmental delay was noted, although he was able to roll from his stomach to his back and bring his hands to his mouth. At home, he started having respiratory problems, with oxygen saturations in the mid 80s. He intermittently developed diaphoresis and tachypnea.
Digital necroses in child with SMA
(A) Left foot. (B) Right hand.
He was readmitted 1.5 weeks later. His mother had additionally noticed a violaceous discoloration of his fingernails (figure, B). Despite heparin, aspirin, methylprednisolone (in case of vasculitis), and a supraclavicular nerve block with the intent of reversing any vasoconstriction, this progressed to severe necrosis. CT angiography and an echocardiogram did not reveal an embolic source. At that time, the child was also found to have clinically recognizable hypotonia, decreased right palmar grasp strength, and a tremulous tongue. On the day of readmission, he went into respiratory failure requiring intubation. A workup for rheumatologic conditions returned negative including an antiphospholipid panel, antinuclear antibodies, cryoglobulin levels, anti-neutrophil cytoplasmic antibodies for myeloperoxidase, anti-neutrophil cytoplasmic antibodies for proteinase 3, adenosine deaminase 2 deficiency, and a cytokine panel. A brain MRI returned normal. Trio whole-exome sequencing was sent, and results were nondiagnostic. An electromyogram demonstrated evidence of possible anterior horn cell dysfunction as can be seen in SMA. SMN1 genetic testing was sent, and PCR amplification showed a homozygous deletion of exons 7 and 8, diagnostic of SMA. In addition, the SMN2 copy number was tested revealing that the patient had only 1 copy of SMN2. The pediatric palliative care team helped elucidate the family's goals for the patient, facilitated a comfort care plan, which included a compassionate extubation, and continued to provide bereavement support for the family.
Discussion
SMA is a result of biallelic intragenic deletions or pathogenic variants in the SMN1 gene located on chromosome 5q13, which cause loss of function of the survival of motor neuron protein (SMN). SMN is ubiquitously expressed, and although SMA is characterized by loss of motor neurons in the ventral horn of the spinal cord, multiple organs, including cardiac, skeletal, and gastrointestinal, are negatively affected as well.2,3 The severity and age at onset span a continuum. Digital necrosis is rare in SMA and has been reported in only 4 other cases, all infants with a severe form of the disease.4,5 Of interest, mouse models for severe SMA given life-prolonging treatments have developed tail and ear necrosis.6 The SMN2 gene is nearly identical to the SMN1 gene except for a single nucleotide change, which causes skipping of its exon 7, resulting in only 10% of its protein product being functional. The copy number of SMN2 varies in the population and inversely correlates with disease severity. In our case, the patient was found to have only 1 copy of SMN2. The antisense oligonucleotide nusinersen was approved for treatment of certain cases of SMA. Nusinersen increases the percentage of SMN2's functional protein product by including transcription of its exon 7.7 This along with other interventions is expected to improve life expectancy. Our patient presented before the approval of this medication, and it is not known whether a manifestation such as a digital necrosis would respond to this new therapy. Further delineation of the phenotype of SMA will aid in uncovering etiologies of the disease's manifestations and directed therapies. This report describes the fifth case of an infant with severe SMA who developed distal digital necrosis. An examination of SMN2 copy number in more of these cases with this unusual and dramatic complication would be useful. Our case highlights the need to consider SMA in the differential diagnosis for infantile digital necrosis.
Study funding
No targeted funding reported.
Disclosure
Disclosures available: Neurology.org/NG.
Appendix Authors
Footnotes
Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
- Received April 30, 2019.
- Accepted in final form August 12, 2019.
- Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy
Practical guidelines to manage discordant situations of SMN2 copy number in patients with spinal muscular atrophy
Molecular Biomarkers for Spinal Muscular Atrophy
Transmission ratio distortion in the spinal muscular atrophy locus